<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423004</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2017-12</org_study_id>
    <nct_id>NCT03423004</nct_id>
  </id_info>
  <brief_title>Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin</brief_title>
  <acronym>EMIP</acronym>
  <official_title>Comparative Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project topic consists on re-conciliating the fine tuners of the gene expression
      &quot;microRNAs&quot; and the immunopathogenic occasions responsible for skin disorders in context of
      skin infection and inflammation such as psoriasis. The skin is a network of effector cells
      and molecular mediators that constitute a highly sophisticated &quot;Skin Immune System (SIS)
      described by Jan D Bos in 1986. The cutaneous homeostasis maintenance is dependent on the
      cross talk between several immune sentinels present in the different compartments of the skin
      as well as the interplay between innate and adaptive immune responses. The whole is under the
      control of gene regulation. However, cutaneous homeostasis disruption occurs when the SIS
      safe framework erroneously sends aggravation signals due to gene regulation disbalance via
      inflammatory cellular and molecular mediators into the site of infection causing chronic
      inflammation characterized by thick red irritated skin lesions. The latter was showed to have
      a characteristic microRNA (regulators of gene expression) signature.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase Ratio</measure>
    <time_frame>Day 0</time_frame>
    <description>Increase ratio between relative expression of different genes (miR-21 and InterLeukin-22) of psoriatic lesional skin and non-psoriatic skin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between Psoriasis Area Severity Index and miR-21 expression</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patient with lesional skin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the sample will be taken by superficial cutaneous biopsy in psoriasic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with healthy skin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>the sample will be taken by superficial cutaneous biopsy in psoriasic patients</description>
    <arm_group_label>Patient with lesional skin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women between 18 and 75

          -  Clinical diagnosis of chronic active psoriasis in non-pustular plaque

          -  Treated locally with topical corticosteroids

        Exclusion Criteria:

          -  Patient who did not give express consent to participate

          -  No affiliation to a social security scheme

          -  Patient treated systemically

          -  Thrombocytopenic patient

          -  Patient known to be HIV-positive

          -  Septic patient

          -  Patient with only facial lesions

          -  Patient with psoriasis with joint involvement

          -  Patient participating in another study

          -  Patient protected under the law (under guardianship or trusteeship)

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali ARAR, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>0033238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie TATSI TOTOUOM</last_name>
    <phone>0033238744086</phone>
    <email>elodie.tatsi-totouom@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali ARAR, Dr</last_name>
      <phone>0033238514786</phone>
      <email>ali.arar@chr-orleans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florence ABDALLAH</last_name>
      <phone>0033238255640</phone>
      <email>florence.abdallah@cnrs.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ali ARAR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009 Oct;9(10):679-91. doi: 10.1038/nri2622. Epub 2009 Sep 18. Review.</citation>
    <PMID>19763149</PMID>
  </reference>
  <reference>
    <citation>Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005 May;152(5):861-7. Review.</citation>
    <PMID>15888138</PMID>
  </reference>
  <reference>
    <citation>Sobhan MR, Farshchian M, Hoseinzadeh A, Ghasemibasir HR, Solgi G. Serum Levels of IL-10 and IL-22 Cytokines in Patients with Psoriasis. Iran J Immunol. 2016 Dec;13(4):317-323. doi: IJIv13i4A8.</citation>
    <PMID>27999243</PMID>
  </reference>
  <reference>
    <citation>Carrascosa JM, Toro Montecinos M, Ballescá F, Teniente Serra A, Martínez Cáceres E, Ferrándiz C. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. J Dermatolog Treat. 2018 Mar;29(2):140-144. doi: 10.1080/09546634.2017.1341619. Epub 2017 Jul 6.</citation>
    <PMID>28604127</PMID>
  </reference>
  <reference>
    <citation>Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009 Aug;10(8):857-63. doi: 10.1038/ni.1767. Epub 2009 Jul 5.</citation>
    <PMID>19578369</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>IL-22</keyword>
  <keyword>miR-21</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

